The AVITA Medical Inc (ASX: AVH) share price is set to finish higher today. This comes after the company announced an update from the United States Food and Drug Administration in regards to its Recell System.
At the time of writing, the regenerative medicine company’s shares are fetching for $2.64, up 6.02%.
What did Avita announce?
In today’s statement, Avita advised it has received approval from the FDA for its Recell Autologous Cell Harvesting Device.
This has led investors to bid up the Avita share price following the positive news from the company.
According to the release, Avita can now begin to supply and market the enhanced Recell system to the United States market.
The Recell System is a device that is used to treat a patient’s acute thermal burns. Healthcare professionals produce a suspension of ‘Spray-On Skin’ cells using a small sample of the patient’s own skin. In turn, this reduces the amount of the donor skin required to heal the burn injury.
The new Recell System has been modified to reduce set-up steps by around one-third and can be operated with reduced support personnel.
This follows the company’s first United States product, the original Recell System, which received FDA approval in September 2018. With the new ease-of-use design now approved, Avita will launch the product in the second quarter of 2022.
Avita CEO, Dr Mike Perry commented:
To ensure Recell continues to meet the needs of our customers, we initiated a program to explore how we could improve the device, and then addressed those matters with this new system.
Based upon research and human factors testing, we are confident that the new Recell System will be positively received by the burn community. The enhancements will provide a range of benefits to clinicians using the device and in turn, patients will benefit as the procedure becomes more efficient.
Avita share price snapshot
The Avita share price has been on a trending decline the past 12 months, reaching a multi-year low of $2.46 last month. Over the period, its shares have lost almost 60%, with year to date down 22%.
Avita commands a market capitalisation of roughly $186.88 million and has approximately 70.89 million shares on its registry.
The post Avita (ASX:AVH) share price jumps 6% following FDA approval appeared first on The Motley Fool Australia.
Should you invest $1,000 in Avita right now?
Before you consider Avita, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Avita wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Why ‘dependable and reliable dividend payers’ could be the antidote to current volatility: expert
- The ASX 200 is awash with 52-week lows on Friday. Here are some of the biggest names growing smaller
- Rural Funds (ASX:RFF) share price jumps on first-half financials
- Brokers name 3 ASX shares to buy today
- Are TPG Telecom (ASX:TPG) shares gearing up for a demerger?
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/LKBIEey
Leave a Reply